Survival pronostic factors in Mexican patients with multiforme glioblastoma
Main Article Content
Keywords
glioblastoma, astrocytoma, neoplasms, survival rate
Abstract
Objective: to study the pre- and transoperative factors that influence patients’ survival with GM.
Methods: clinical and pathological records of all confirmed cases of GM diagnosed between 2000 and 2006 were included. Postoperative survival was divided in less or more than 8 months. χ2 test was used.
Results: one hundred and twenty patients (45 women and 75 men) were studied. Age range was from 7 to 85 years, 3.3 % were 16 years old or younger and 12.5 % were 70 years old or older. Headache was the most frequent complain, 40 patients developed hemiparesia and 6 had pares-tesias. Predominance of white matter hemispheric lesions was observed: right hemispheric tumors 65 (54 %), left lesions 30 (25 %) and bilateral tumors 7 %. Histologically, 1.6 % of GM had a sarcomatous component; 35 % of patients survived less than 8 months. A difference between patients survival was the preoperative Karnofsky Performance Scale Score and the degree of cerebral edema during the surgical procedure.
Conclusions: pre-operative Karnofsky evaluation and edema during the surgical procedure were significant prognostic factors for survival.
References
Yasargil MG. Legacy of microneurosurgery: memoirs, lessons, and axioms. Neurosurgery 1999;45(5):1025-1092.
Burger PC, Vogel FS, Green SB, Strike TA. Glioblastoma multiforme and anaplas-tic astrocytoma. Pathologic criteria and prognostic implications. Cancer 1985; 56(5):1106-1111.
Centro Nacional de Vigilancia Epidemiológica y Control de Enfermedades. Registro histopatológico de neoplasias malignas en México, 2002. México: Secretaría de Salud; 2003.
López-González MA, Sotelo J. Brain tumors in Mexico: characteristics and prognosis of glioblastoma. Surg Neurol 2000;53(2):157-162.
Mineo JF, Quintin-Roue I, Lucas B, Buburusan V, Besson G. Glioblastomas: cli-nical study and search for prognostic factors. Neurochirurgie 2002;48(6):500-509.
Bouvier-Labit C, Chinot O, Ochi C, Gambarelli D, Dufour H, Figarella-Branger D. Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas. Neuropathol Appl Neurobiol 1998;24 (5):381-388.
Von Deimling A, Louis DN, von Ammon K, Petersen I, Hoell T, Chung RY, et al. Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J Neurosurg 1992; 77(2):295-301.
Korkolopoulou P, Christodoulou P, Kouzelis K, Hadjiyannakis M, Priftis A, Stamoulis G, et al. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer 1997;75(9):1269-1278.
Ekstrand AJ, Sugawa N, James CD, Collins VP. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci USA 1992;89(10):4309-4313.
Duerr EM, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, Louis DN, et al. PTEN mutations in gliomas and glioneuronal tumors. Oncogene 1998;16 (17):2259-2264.
Nalabothula N, Lakka SS, Dinh DH, Gujrati M, Olivero WC, Rao JS. Sense p16 and antisense uPAR bicistronic construct inhibits angiogenesis and induces glioma cell death. Int J Oncol 2007;30(3):669-678.
Bian XW, Yang SX, Chen JH, Ping YF, Zhou XD, Wang QL, et al. Preferential expression of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival. Neurosurgery 2007;61(3): 570-579.
Simon M, Ludwig M, Fimmers R, Mahlberg R, Müller-Erkwoh A, Köster G, et al. Variant of the CHEK2 gene as a prognostic marker in glioblastoma multiforme. Neurosurgery 2006;59(5):1078-1085.
Hotfilder M, Knupfer H, Mohlenkamp G, Pennekamp P, Knupfers M, Van Gool S, et al. Interferon-gamma increases IL-6 production in human glioblastoma cell lines. Anticancer Res 2000;20 (6B):4445-4450.
Aoki T, Takahashi JA, Ueba T, Oya N, Hiraoka M, Matsui K, et al. Phase II study of nimustine, carbo-platin, vincristine, and interferon-B with radiotherapy for glioblastoma multiforme: experience of the Kyoto Neuro-Oncology Group. J Neurosurg 2006;105(3): 385-391.
Hau P, Koch D, Hundsberger T, Marg E, Bauer B, Rudolph R, Rauch M, et al. Safety and feasibility of longterm temozolomide treatment in patients with highgrade glioma. Neurology 2007;68(9):688-690.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-996.
Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007; 356(15):1527-1535.
Ferroli P, Broggi M, Franzini A, Maccagnano E, Lamperti M, Boiardi A, et al. Surgifoam and mitoxantrone in the glioblastoma multiforme postresection cavity: the first step of locoregional chemotherapy through an ad hoc-placed catheter: technical note. Neurosurgery 2006;59(2):E4 33-434.
Gabayan A, Green S, Sanan A. GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis. Neurosurgery 2006; 58(4):701-709.
Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prog-nosis, extent of resection, and survival. J Neurosurg 2001;95(2):190-198.
Ulutin C, Fayda M, Aksu G, Cetinayak O, Kuzhan O, Ors F, et al. Primary glioblastoma multiforme in younger patients: a singleinstitution experience. Tumori 2006;92(5):407-411.
Schankin CJ, Ferrari U, Reinisch VM, Birnbaum T, Goldbrunner R, Straube A. Characteristics of brain tumor-associated headache. Cephalalgia 2007;27 (8):904-911.
Alatakis S, Stuckey S, Siu K, McLean C. Gliosarcoma with osteosarcomatous differentiation: review of radiological and pathological features. J Clin Neurosci 2004;11(6):650-656.
Galanis E, Buckner JC, Dinapoli RP, Scheithauer BW, Jenkins RB, Wang CH, et al. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results. J Neurosurg 1998;89(3):425-430.
Borota OC, Scheie D, Bjerkhagen B, Jacobsen EA, Skullerud K. Gliosarcoma with liposarco- matous component, bone infiltration and extracranial growth. Clin Neuropathol 2006;25(4): 200-203.
Larjavaara S, Mäntylä R, Salminen T, Haapasalo H, Raitanen J, Jääskeläinen J, et al. Incidence of gliomas by anatomic location. Neuro Oncol 2007; 9(3):319-325.
Utsuki S, Oka H, Suzuki S, Shimizu S, Tanizaki Y, Kondo K, et al. Pathological and clinical features of cystic and noncystic glioblastomas. Brain Tumor Pathol 2006;23(1):29-34.
Mineo JF, Bordron A, Baroncini M, Ramírez C, Maurage CA, Blond S, et al. Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients. Acta Neurochir 2007;149(3):245-252.
Jeremi B, Grulici D, Samardzi M, Antunovi V, Joksimovi M, Djuri LJ, et al. The effect of extent of tumor resection on the outcome of combined therapy in patients with glioblastoma multiforme. Srp Arh Celok Lek 1997;125(3-4):93-98.
Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF. MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 2005;26(10):2466-2474.
Stashuk GA, Balkanov AS. The comparison of glioblastoma and its surrounding edema by MRI of brain. Vestn Rentgenol Radiol 2006;(3):19-23.
Jain RK, di Tomaso E, Duda DG, Loeffler JS, So-rensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007;8(8):610-622.
Perry J, Laperriere N, Zuraw L, Chambers A, Spit-hoff K, Cairncross JG, et al. Adjuvant chemotherapy for adults with malignant glioma: a systematic review. Can J Neurol Sci 2007;34(4):402-410.
Liu C, Sarkaria JN, Petell CA, Paraskevakou G, Zollman PJ, Schroeder M, et al. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Clin Cancer Res 2007;13(23):7155-7165.
Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M, et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res 2007;67(23):11244-11253.